Infection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-α
Authors: Hervé Zylberberg, M. L. Chaix, Christian Bréchot
Journal: Annals of Internal Medicine (2000)

Letters16 May 2000Infection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-αHervé Zylberberg, MD, M. L. Chaix, MD, and Christian Bréchot, MD, PhDHervé Zylberberg, MDHôpital Necker; 75747 Paris, France (Zylberberg)Hôpital Necker; 75747 Paris, France (Chaix)Hôpital Necker; 75747 Paris, France (Bréchot), M. L. Chaix, MDHôpital Necker; 75747 Paris, France (Zylberberg)Hôpital Necker; 75747 Paris, France (Chaix)Hôpital Necker; 75747 Paris, France (Bréchot), and Christian Bréchot, MD, PhDHôpital Necker; 75747 Paris, France (Zylberberg)Hôpital Necker; 75747 Paris, France (Chaix)Hôpital Necker; 75747 Paris, France (Bréchot)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-10-200005160-00029 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The hepatitis C virus (HCV) genotype is a crucial predictive factor of response to interferon-α and is associated with the route of infection (1, 2). Although HCV genotype 4 is generally assumed to be resistant to interferon-α therapy, detailed studies on this issue are still lacking (3, 4).We studied 74 (5%) patients infected with HCV genotype 4 out of the 1520 HCV-infected patients in our files who had undergone genotyping. Genotype and quantitative viremia were assessed by the Inno-Lipa (Innogenetics, Zwijnaarde, Belgium) and Monitor (Hoffman-LaRoche, Meylan, France) assays, respectively.The risk factors were blood transfusion in ...References1. Simmonds P, Holmes EC, Cha TA, Chan TA, Chan SW, McOmish F, et al . Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74:2391-9. CrossrefMedlineGoogle Scholar2. Nousbaum JP, Pol S, Nalpas B, Landais B, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy: collaborative study group. Ann Intern Med. 1995;122:161-8. LinkGoogle Scholar3. El-Zavadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Adhy A. Response of chronic hepatitis C type 4 Egyptian patients to α-interferon [Abstract]. IASL. 1996; 17T. Google Scholar4. Remy AJ, Verdier E, Perney P, Ducos J, Blanc P, Blanc F, et al . Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a western country. J Hepatol. 1998;29:169. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hôpital Necker; 75747 Paris, France (Zylberberg)Hôpital Necker; 75747 Paris, France (Chaix)Hôpital Necker; 75747 Paris, France (Bréchot) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHepatitis C Virus Genotype 4 and Response to Combination Therapy with Interferon-α2b plus Ribavirin Savino Bruno , Andrea Crosignani , and Giovanni Battista Pinzello Infection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-α Morris Sherman , George Marinos , and Farhad Sedarati Optimized Virologic Response in Hepatitis C Virus Genotype 4 with Peginterferon-α2a and Ribavirin Moises Diago , Tarek Hassanein , Juan Rodés , Andrew M. Ackrill , and Farhad Sedarati Metrics Cited ByCurrent status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysisComparison of three different HCV genotyping methods: Core, NS5B sequence analysis and line probe assayNew insights into hepatitis C virus infection in the tribal-dominant part of Northeast IndiaPredictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?Hepatitis C Genotype 4 Therapy: Progress and ChallengesHepatitis C virus infection in a population with high incidence of type 2 diabetes: Impact on diabetes complicationsManagement of hepatitis C virus genotype 4: Recommendations of An International Expert PanelHepatitis C virus genotype 4 therapy: progress and challengesInsulin Resistance Predicts Rapid Virologic Response to Peginterferon/Ribavirin Combination Therapy in Hepatitis C Genotype 4 PatientsThe neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus reportRisk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infectionHepatitis C genotype 4 therapy: increasing options and improving outcomesPredictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4Hepatitis C genotype 4: What we know and what we don't yet knowChapter 2 Cutting the Gordian Knot-Development and Biological Relevance of Hepatitis C Virus Cell Culture SystemsPegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic responseImproving Outcome in Patients With Hepatitis C Virus Genotype 4Clinical and Pathological Characteristics and Response to Combination Therapy of Genotype 4 Chronic Hepatitis C Patients: Experience from a Spanish CenterIn Vitro Infection of Immortalized Primary Hepatocytes by HCV Genotype 4a and Inhibition of Virus Replication by CyclosporinDetecção do genótipo 4 do vírus da hepatite C em Salvador, BAGenotypic variations around the world: Is hepatitis C virus evolving?Distribution of hepatitis C virus genotypes in the Middle EastPegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infectionChronic Hepatitis C: Genotypes 4 to 9Molecular methods of hepatitis C genotypingGeographic distribution of hepatitis C virus genotypes in BrazilHCV genotype 4—an emerging threat as a cause of chronic liver disease in Indian (south) patientsPegylating IFNs at His-34 Improves the in Vitro Antiviral Activity Through the JAK/STAT PathwayManagement of hepatitis C virus genotype 4Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well?Stefan Zeuzem, MDOptimized Virologic Response in Hepatitis C Virus Genotype 4 with Peginterferon-α2a and RibavirinMoises Diago, MD, Tarek Hassanein, MD, Juan Rodés, MD, Andrew M. Ackrill, PhD, and Farhad Sedarati, PhDInfection with Hepatitis C Virus Genotype 4 in the United StatesEffects of the CCR5-Δ32 mutation on antiviral treatment in chronic hepatitis CSustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferonLiver transplantation for HCV-associated liver cirrhosis: Predictors of outcomes in a population with significant genotype 3 and 4 distributionInfection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-αMorris Sherman, MD, George Marinos, MD, and Farhad Sedarati, PhDHepatitis C Virus Genotype 4 and Response to Combination Therapy with Interferon-α2b plus RibavirinSavino Bruno, MD, Andrea Crosignani, MD, and Giovanni Battista Pinzello, MDTreatment of Chronic Hepatitis C with Different Genotypes 16 May 2000Volume 132, Issue 10Page: 845-846KeywordsCirrhosisDrugsGenotypingHIV infectionsHepatitis AHepatitis C virusMedical risk factorsRNAViral loadViremia Issue Published: 16 May 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...